Akebia Therapeutics Institutional Investor Sentiment Worsened in Q3 2018

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Logo

Sentiment for Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics (NASDAQ:AKBA) institutional sentiment decreased to 0.89 in Q3 2018. Its down -0.46, from 1.35 in 2018Q2. The ratio dived, as 49 hedge funds increased or started new holdings, while 55 sold and reduced their holdings in Akebia Therapeutics. The hedge funds in our partner’s database now own: 38.94 million shares, down from 39.91 million shares in 2018Q2. Also, the number of hedge funds holding Akebia Therapeutics in their top 10 holdings decreased from 2 to 1 for a decrease of 1. Sold All: 19 Reduced: 36 Increased: 34 New Position: 15.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology. The company has market cap of $728.21 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. It currently has negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

The stock decreased 0.95% or $0.06 during the last trading session, reaching $6.23. About 534,157 shares traded. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has declined 42.65% since January 14, 2018 and is downtrending. It has underperformed by 42.65% the S&P500.

Analysts await Akebia Therapeutics, Inc. (NASDAQ:AKBA) to report earnings on March, 11. They expect $-0.80 earnings per share, down 420.00 % or $1.05 from last year’s $0.25 per share. After $-0.46 actual earnings per share reported by Akebia Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 73.91 % negative EPS growth.

Dafna Capital Management Llc holds 2.27% of its portfolio in Akebia Therapeutics, Inc. for 625,738 shares. Nantahala Capital Management Llc owns 4.72 million shares or 1.12% of their US portfolio. Moreover, Opus Point Partners Management Llc has 0.95% invested in the company for 45,004 shares. The Alabama-based Stanley has invested 0.65% in the stock. Perceptive Advisors Llc, a New York-based fund reported 2.45 million shares.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Coverage

Ratings analysis reveals 50% of Akebia Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Akebia Therapeutics, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $9 while the high is $18. The stock’s average target of $13.50 is 116.69% above today’s ($6.23) share price. AKBA was included in 2 notes of analysts from August 14, 2018. The rating was maintained by Morgan Stanley on Friday, September 7 with “Equal-Weight”.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.